Table 5.
Tumor Biological Characteristics of Patients for Whom Samples of Both Primary Tumor and Metastasis were Available
| Primary Tumor (n = 33) |
Metastasis (n = 33) |
|
|---|---|---|
| No. (%) | No. (%) | |
| Grade | ||
| 1 | 1 (4.5) | 0 |
| 2 | 8 (36.4) | 5 (50.0) |
| 3 | 13 (59.1) | 5 (50.0) |
| Unknown | 11 | 23 |
| ER status | ||
| <1% | 5 (17.2) | 4 (12.5) |
| ≥1% | 24 (82.8) | 28 (87.5) |
| Unknown | 4 | 1 |
| PgR status | ||
| <1% | 7 (24.1) | 18 (56.2) |
| ≥1% | 22 (75.9) | 14 (43.8) |
| Unknown | 4 | 1 |
| <20% | 13 (44.8) | 18 (58.1) |
| ≥20% | 16 (55.2) | 13 (41.9) |
| Unknown | 4 | 2 |
| Ki67 status | ||
| <20% | 12 (41.4) | 18 (58.1) |
| ≥20% | 17 (58.6) | 13 (41.9) |
| Unknown | 4 | 2 |
| HER2 status | ||
| Negative | 23 (85.2) | 28 (90.3) |
| Positive | 4 (14.8) | 3 (9.7) |
| Unknown | 6 | 2 |
| AR status | ||
| <1% | 4 (12.1) | 11 (33.3) |
| ≥1% | 29 (87.9) | 22 (66.7) |
| Unknown | 0 | 0 |
| <10 | 4 (12.1) | 15 (45.5) |
| ≥10 | 29 (87.9) | 18 (54.5) |
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor.